company mission
Scholar Rock's mission did not swing wildly between 2013 and 2017. On February 5, 2013, it described itself in broad biotech terms: an early stage company discovering and developing novel biologic therapeutics. By January 11, 2014, the language became much more specific. The company said it was targeting the disease microenvironment, aiming biologic therapies at disease-causing proteins located there, with a proprietary approach for highly selective targeting of growth factors. That sharper framing held up in the later record. On April 21, 2017, Scholar Rock still centered the same basic idea: selective biologic therapies acting at the source of disease through the microenvironment, with growth factors as the core target. The newer wrinkle was mechanistic language, especially the claim that modulating supracellular activation could produce those effects. That reads like refinement, not a reset. So the stable belief is clear: Scholar Rock saw its identity in targeted biologics built around selective control of growth-factor biology in diseased tissue contexts. What changed was the level of precision. The company moved from a generic biotech mission to a tighter, more technical statement of how and where it thought intervention should happen. Evidence is thin because the timeline only includes three website snapshots, all corporate self-description, so we can trace messaging quite well but not internal strategic debates or any abandoned variants.